Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism

This is a copy of an article published in the ANTIOXIDANTS & REDOX SIGNALING (15-08-2011) copyright Mary Ann Liebert, Inc. ANTIOXIDANTS & REDOX SIGNALING is avalaible online at: http://online.liebertpub.com

Detalles Bibliográficos
Autores: Jaźwa, Agnieszka, Rojo Sanchís, Ana Isabel, Innamorato, Nadia G., Hesse, Marlen, Fernández-Ruíz, Javier Javier, Cuadrado Pastor, Antonio
Tipo de recurso: artículo
Fecha de publicación:2011
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/667893
Acceso en línea:http://hdl.handle.net/10486/667893
https://dx.doi.org/10.1089/ars.2010.3731
Access Level:acceso abierto
Palabra clave:Symptoms of Parkinson’s disease
Therapies
Factor Nrf2
Medicina
id ES_c82832fc7e3babcdc4e9a5ec693af681
oai_identifier_str oai:repositorio.uam.es:10486/667893
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonismJaźwa, AgnieszkaRojo Sanchís, Ana IsabelInnamorato, Nadia G.Hesse, MarlenFernández-Ruíz, Javier JavierCuadrado Pastor, AntonioSymptoms of Parkinson’s diseaseTherapiesFactor Nrf2MedicinaThis is a copy of an article published in the ANTIOXIDANTS & REDOX SIGNALING (15-08-2011) copyright Mary Ann Liebert, Inc. ANTIOXIDANTS & REDOX SIGNALING is avalaible online at: http://online.liebertpub.comCurrent therapies for motor symptoms of Parkinson’s disease (PD) are based on dopamine replacement. However, the disease progression remains unaffected, because of continuous dopaminergic neuron loss. Since oxidative stress is actively involved in neuronal death in PD, pharmacological targeting of the antioxidant machinery may have therapeutic value.Here,we analyzed the relevance of the antioxidant phase II responsemediated by the transcription factor NF-E2-related factor 2 (Nrf2) on brain protection against the parkinsonian toxin methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Intraperitoneal administration of the potentNrf2 activator sulforaphane (SFN) increased Nrf2 protein levels in the basal ganglia and led to upregulation of phase II antioxidant enzymes heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase (NQO1). In wild-type mice, but not in Nrf2-knockout mice, SFN protected against MPTP-induced death of nigral dopaminergic neurons. The neuroprotective effects were accompanied by a decrease in astrogliosis, microgliosis, and release of pro-inflammatory cytokines. These results provide strong pharmacokinetic and biochemical evidence for activation ofNrf2 and phase II genes in the brain and also offer a neuroprotective strategy that may have clinical relevance for PD therapyThis work was supported by a Target Validation Grant of the Michael J. Fox Foundation for Parkinson’s Research and grant SAF2010-17822 from the Spanish Ministery of Science and Innovation.Mary Ann Liebert, Inc.Departamento de BioquímicaFacultad de Medicina20112011-06-15research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/667893https://dx.doi.org/10.1089/ars.2010.3731reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/6678932026-06-23T12:46:27Z
dc.title.none.fl_str_mv Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
title Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
spellingShingle Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
Jaźwa, Agnieszka
Symptoms of Parkinson’s disease
Therapies
Factor Nrf2
Medicina
title_short Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
title_full Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
title_fullStr Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
title_full_unstemmed Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
title_sort Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism
dc.creator.none.fl_str_mv Jaźwa, Agnieszka
Rojo Sanchís, Ana Isabel
Innamorato, Nadia G.
Hesse, Marlen
Fernández-Ruíz, Javier Javier
Cuadrado Pastor, Antonio
author Jaźwa, Agnieszka
author_facet Jaźwa, Agnieszka
Rojo Sanchís, Ana Isabel
Innamorato, Nadia G.
Hesse, Marlen
Fernández-Ruíz, Javier Javier
Cuadrado Pastor, Antonio
author_role author
author2 Rojo Sanchís, Ana Isabel
Innamorato, Nadia G.
Hesse, Marlen
Fernández-Ruíz, Javier Javier
Cuadrado Pastor, Antonio
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Bioquímica
Facultad de Medicina
dc.subject.none.fl_str_mv Symptoms of Parkinson’s disease
Therapies
Factor Nrf2
Medicina
topic Symptoms of Parkinson’s disease
Therapies
Factor Nrf2
Medicina
description This is a copy of an article published in the ANTIOXIDANTS & REDOX SIGNALING (15-08-2011) copyright Mary Ann Liebert, Inc. ANTIOXIDANTS & REDOX SIGNALING is avalaible online at: http://online.liebertpub.com
publishDate 2011
dc.date.none.fl_str_mv 2011
2011-06-15
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/667893
https://dx.doi.org/10.1089/ars.2010.3731
url http://hdl.handle.net/10486/667893
https://dx.doi.org/10.1089/ars.2010.3731
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Mary Ann Liebert, Inc.
publisher.none.fl_str_mv Mary Ann Liebert, Inc.
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419261792878592
score 15,300719

Similares en LA Referencia